Abstract
Immunophenotypic and genetic analyses have become routine in the diagnosis and monitoring of hematological malignancies in the developed world. However, these advances have not been translated to developing countries. The technology required is expensive and has previously not been available.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have